CDT Equity Inc. filings document a Nasdaq-listed biopharmaceutical issuer with common stock and redeemable warrants, a Delaware corporate structure, and an R&D-focused business built around clinical assets, intellectual property and strategic investments. Current reports and proxy materials cover material agreements, Sarborg-related securities transactions, equity line arrangements, warrant issuances, resale registration obligations and Nasdaq shareholder-approval matters.
The filing record also addresses capital-structure changes such as reverse stock split amendments, voting results, director appointments, committee membership and Exchange Act reporting status, including annual-report timing notices. These disclosures describe CDT's governance framework, security-holder rights and financing tools.
CDT Equity Inc.'s amendment reports that Primary Development Fund (Cayman) SPC, E2 Trust, E3 Fund SP and IALC Trustees SA each reported shared beneficial ownership of 50,321 common shares, or 3.4% of the class, and had ceased to be a beneficial owner of more than 5%. The same shares are attributed to all four reporting persons, not separate blocks.
Primary Development Fund directly held the shares on behalf of E3 Fund. E2 Trust held a 95% beneficial interest in E3 Fund, and Altug Family Trust held 5%. CDT had 1,477,789 shares outstanding as of September 30, 2026; the reported holdings reflect the 1-for-25 reverse split effected September 28, 2026.
CDT Equity Inc. is the issuer whose common shares are reported as beneficially owned by Primary Development Fund (Cayman) SPC, E2 Trust, E3 Fund SP and IALC Trustees SA. Each reporting person's disclosure lists the same 50,321-share block, equal to 9.2%, with shared voting and dispositive power; the reporting persons may be deemed to share beneficial ownership of shares directly held by Primary Development Fund. The reported share count is as of August 31, 2026 and gives effect to the 1-for-25 reverse split effected September 28, 2026. Sam Bratchie is listed as a Director and Administrator; Ian Altug is listed as Director of Corporate Trustee to E2 Trust - IALC Trustees and as a Director.
CDT Equity Inc.’s ownership amendment reports that Mark Taylor, Prospect Capital Securities Limited and Prospect Finance Limited each ceased to be beneficial owners of more than 5% of its common stock. Prospect Capital Securities Limited and Prospect Finance Limited each directly owned 25,161 shares, or 1.7%, as of September 30, 2026.
Taylor directly owned no shares but may be deemed to beneficially own 50,322 shares, or 3.4%, through his roles as sole director and sole shareholder of each company; he disclaims beneficial ownership except to the extent of his pecuniary interest. The percentages use 1,477,789 CDT shares outstanding as of September 30, 2026, and the reported share counts give effect to the 1-for-25 reverse split effected September 28, 2026.
CDT Equity Inc.'s ownership disclosure was amended to report that Craig Wigglesworth, the reporting person, directly owned 50,322 common shares, approximately 3.4% of the class, as of September 30, 2026. The percentage was based on 1,477,789 shares outstanding that day. Mr. Wigglesworth ceased to be a beneficial owner of more than 5%, making this an exit filing. The reported share count reflects the 1-for-25 reverse split effected September 28, 2026. He reported sole voting and dispositive power over 50,322 shares and disclaimed beneficial ownership except to the extent of his pecuniary interest.
CDT Equity Inc. is registering 673,023 shares of common stock for resale by selling stockholders. CDT is not selling securities in this offering and will receive no proceeds from their sales; holders may sell any, all or none of the shares. The registered pool includes 485,244 shares issued to Sarborg Limited shareholders, 26,000 shares issued to Sarborg, 140,925 shares issuable to J.J. Astor & Co. under convertible notes, and up to 14,630 shares issuable under warrants. Selling stockholders may sell in public or private transactions at prevailing market prices, prices related to prevailing market prices, or privately negotiated prices.
A 1-for-25 reverse stock split became effective on September 28, 2026, at 5:00 p.m. Eastern Time, combining every 25 issued or outstanding common shares into one. No fractional shares were issued, and holders otherwise entitled to fractions received cash in lieu. CDT said the split was intended to ensure continued compliance with Nasdaq’s bid-price rule. The split left par value unchanged at $0.0001 per share. CDT said outstanding shares would be reduced to approximately 1,124,515 after the split, with proportional adjustments to shares issuable under equity awards, convertible securities and warrants, related exercise prices, and equity-plan reserves.
CDT Equity Inc. will effect a 1-for-25 reverse stock split on September 28, 2026, at 5:00 p.m. Eastern Time. The company expects its common stock to begin trading on a split-adjusted basis at market open on September 29, 2026, under ticker CDT. After the split, outstanding common shares are expected to be approximately 1,124,515. The $0.0001 par value per share will remain unchanged, with proportional adjustments to shares issuable under equity awards, convertible securities, warrants, and equity incentive plans. No fractional shares will be issued; eligible holders will receive cash based on the fraction multiplied by the September 28 closing price per share, adjusted for the split. The company said the split is intended to ensure continued compliance with Nasdaq’s bid-price rule.
CDT Equity Inc. (CDT) is registering 16,825,644 shares of common stock for resale by existing selling stockholders, including warrant shares, conversion shares from prior notes, consulting share issuances, and shares issued in the Sarborg Limited transactions; CDT is not selling any securities here and will not receive proceeds from these resales.
The company previously effected a 1-for-10 reverse stock split of its common stock effective July 17, 2026, and all share and price data in the registration are split-adjusted. Separately, CDT entered into a new senior secured convertible promissory note with J.J. Astor & Co. for $2,126,250 principal (funding $1,575,000, net $1,501,850), maturing March 1, 2027 and payable in 24 weekly installments of $88,593.75, together with related warrants for 3,468,500 shares at $0.25 per share.
The note is secured by a first-priority lien on company and subsidiary collateral and is convertible, subject to ownership caps and stockholder approval under Nasdaq rules, at a price equal to the greater of 70% of the lowest 20-day VWAP or a $0.05 floor price, with the floor subject to semi-annual reset based on trading prices. Most net proceeds from CDT’s at-the-market program and other equity financings are required to be applied in a waterfall to repay this and related Astor notes before other uses, and both the note and warrant include anti-dilution and reset mechanics, as well as 4.99%–9.99% beneficial ownership limitations.
CDT Equity Inc. (CDT) entered into new financing by issuing a senior secured convertible promissory note to J.J. Astor & Co. on September 14, 2026, with a principal amount of $2,126,250, maturing March 1, 2027 and payable in twenty-four weekly installments of $88,593.75.
The company received net proceeds of $1,501,850 and issued Common Stock Purchase Warrants to the lender for 3,468,500 shares at an exercise price of $0.25 per share, exercisable immediately for five years. The note is secured by a first-priority lien on collateral of CDT Equity Inc. and its subsidiary guarantor. Subject to limitations, the lender may convert outstanding amounts into common stock at the greater of 70% of the lowest 20-day volume-weighted average price or a $0.05 floor price, which is subject to semi-annual reset. Conversion and warrant share issuances are capped by a 4.99% (optionally 9.99%) beneficial ownership limit and require stockholder approval under Nasdaq rules, with a meeting to be held if requested, but no later than October 31, 2026.
CDT Equity Inc. (CDT) is registering up to 16,825,644 shares of common stock for resale by existing security holders, including shares issued or issuable under convertible notes, warrants, consulting arrangements, and equity paid in connection with Sarborg Limited transactions. The company is not selling shares itself and will receive no proceeds from these resales.
The prospectus reflects a 1‑for‑10 reverse stock split effective July 17, 2026 and shows 19,268,220 shares outstanding as of the prospectus date, with a last reported Nasdaq Capital Market price of $0.19 on September 17, 2026. CDT highlights heavy reliance on two lead clinical assets (AZD1656 and AZD5904), ongoing net losses, a going‑concern warning, and material weaknesses in internal control, and discloses highly dilutive financing structures including senior secured convertible notes with variable conversion pricing and large warrant and pre‑funded warrant issuances.